Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Core Viewpoint - Anixa Biosciences has completed dosing of the fourth cohort in its Phase 1 clinical trial for a novel FSHR-targeted CAR-T/CER-T therapy aimed at treating recurrent ovarian cancer, maintaining a positive safety profile throughout the trial [1] Group 1 - The company is focused on the treatment and prevention of cancer [1] - The ongoing clinical trial is registered under ClinicalTrials.gov with the identifier NCT05316129 [1] - No dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity have been observed in the trial [1]